PCAC Two-Day Verdict: Six of Seven Peptides Recommended, Emideltide Rejected — and What the Rulemaking Path Means for Research Access

Key takeaways

• The PCAC voted to recommend six of the seven peptides reviewed on 23–24 July 2026 for inclusion on the FDA's Section 503A Bulk Drug Substances List.
• Emideltide (DSIP) was the sole rejection, defeated by a single vote, 6–7.
• All votes were advisory and non-binding; formal notice-and-comment rulemaking must follow before any compounding pharmacy gains a legal pathway.
• Legal analysts estimate realistically no unambiguous 503A compounding access before sometime in 2027.
• A second PCAC meeting covering five additional peptides — LL-37, GHK-Cu, Dihexa acetate, Melanotan II, and PEG-MGF — is scheduled before the end of February 2027.
• Conflict-of-interest concerns about the panel's composition drew sustained criticism during and after the meeting.

The final scoreboard

The FDA's Pharmacy Compounding Advisory Committee concluded its two-day meeting on 24 July 2026 with the following outcome across all seven peptides reviewed.

Day one (23 July): The PCAC voted to recommend all four peptides reviewed that day — BPC-157, KPV, TB-500 and MOTS-c — for inclusion on the Section 503A Bulk Drug Substances List. For BPC-157, KPV and TB-500 the vote was 8–6 with one abstention each time; MOTS-c was closer at 7–5 with two abstentions.

Day two (24 July): The panel voted 7–4 to add epitalon, and 8–5 to add semax. Emideltide, under consideration for opioid withdrawal, chronic insomnia and narcolepsy, failed by a tally of 6–7 — the narrowest result of the two days and the panel's only pushback across the full meeting.

The overall outcome was therefore six positive recommendations and one negative from a total of seven peptides evaluated under docket FDA-2025-N-6895, which had attracted approximately 1,860 public comments ahead of the meeting.

Why Emideltide was the exception

Emideltide (DSIP) has the longest human research history of the seven peptides reviewed, having been studied since the early 1980s, primarily for insomnia and opioid withdrawal. That history, paradoxically, may have worked against it. According to ExcelMale's post-vote analysis, panelists raised a mechanistic concern that DSIP stimulates endorphin release, with several members worried that this resembled the reward-pathway activity associated with addictive drugs.

Fierce Pharma reported that some members who voted in favour of emideltide suggested in their explanations that other panelists may have been straying from the purpose of the advisory committee. Tennessee state Senator Bobby Harshbarger, one of the eight temporary members appointed ahead of the meeting, reportedly indicated his affirmative vote was made "because our duty is to apply the 503A standards, not the Investigational New Drug Application standard," according to Fierce Pharma.

The loss by a single vote leaves open the question of whether emideltide's nominators may seek to re-submit the compound in a future PCAC cycle.

The panel composition controversy

Ahead of the meeting, the FDA added eight temporary voting members to the PCAC. Kennedy's office nominated them, and six have sold peptide products themselves. On BPC-157, KPV and TB-500, all eight new members voted in favour as a bloc. That pattern drew public conflict-of-interest criticism before and during the meeting.

STAT News reported on 24 July that the two-day meeting highlighted broader tensions between the Make America Healthy Again movement and mainstream scientists, with the fundamental question facing panelists being whether it is acceptable to let individuals take medicines of unclear safety or efficacy.

It is worth noting, as STAT News observed, that the votes bring Health Secretary Robert F. Kennedy Jr. one step closer to his stated mission of making these unapproved compounds more available to Americans. The FDA, however, is not bound by advisory committee recommendations.

Three legal events — not one

A common error in coverage of this meeting is conflating three distinct regulatory milestones. LumaLex Law's founding partner Dustin Robinson explained to PharmExec that there are "three distinct legal events the market keeps treating as one: removal from Category 2, a PCAC recommendation, and actual placement on the Category 1 compoundable list following notice-and-comment rulemaking."

For research-procurement professionals, the sequence matters greatly:

1. Category 2 removal — Completed in April 2026 for all twelve peptides in the current review cycle. This permits review but not compounding.
2. PCAC recommendation — Completed 23–24 July 2026 for the first seven. Advisory only; the FDA may accept, modify or reject each recommendation.
3. Formal rulemaking — A proposed rule must be published, a public comment period must run, and a final rule must be issued before a 503A pharmacy has unambiguous legal authority to compound any of these substances.

According to Robinson, the advisory committee's recommendation still triggers a formal rulemaking cycle that realistically runs eight to twelve months before 503A pharmacies have unambiguous legal authority to compound these substances.

ExcelMale's post-vote analysis reached a similar conclusion: PCAC votes are non-binding, and the FDA still has to complete formal rulemaking — a proposed rule, a comment period, then a final rule — before any of these six can legally be compounded under 503A, a process that has typically taken well over a year to reach even a proposed rule after a positive vote. Realistic pharmacy access, the same source assessed, is more likely sometime in 2027.

Orrick noted that the administration may attempt to accelerate this timeline or use interim enforcement discretion, such as Category 1 designation, as a bridge, but the formal rulemaking requirement cannot be bypassed entirely.

The February 2027 PCAC meeting

The July meeting addressed only seven of the twelve peptides removed from Category 2 in April 2026. The remaining five will be reviewed at a second PCAC meeting. A second PCAC meeting is expected to be scheduled before the end of February 2027 and will address five additional peptides: LL-37 (cathelicidin), GHK-Cu, Dihexa acetate, Melanotan II, and PEG-MGF.

According to Olympia Pharmacy, the FDA has not yet posted the final date and time for that meeting, with the agency stating that additional details and a public comment docket will be published later.

Newtropin's regulatory tracker noted that LL-37, Dihexa, Melanotan II and PEG-MGF were all previously in a "withdrawn, no active review" state and are now being reconsidered — a meaningful shift for compounds that had effectively been off the regulatory agenda.

Compounds outside this cycle

Research labs should note that several peptides commonly sourced alongside those reviewed in July remain on a separate regulatory track. PeptideClarity's tracker records that CJC-1295, Ipamorelin, AOD-9604 and Thymosin Alpha-1 were referred to PCAC in September 2024 but the committee voted against all four at meetings in October and December 2024. Selank has not been scheduled for review at either of the two announced PCAC meetings.

Peptide Stack confirmed that the FDA's concerns regarding ipamorelin included serious adverse events, including one death, in a study where ipamorelin was administered intravenously for improving gastric motility — a safety record that informed its 2024 rejection and that is unlikely to be reconsidered rapidly in the current review environment.

What procurement professionals should watch

The practical implications for UK and European research-procurement teams are limited in the short term, since the 503A framework governs US compounding pharmacies dispensing against individual US prescriptions. However, regulatory direction in the US typically influences sourcing confidence and supplier behaviour globally.

Sheppard Mullin's regulatory team noted an important layer below the federal picture: state boards of pharmacy maintain independent authority over compounding practices, and several states have adopted positions on peptide compounding that are more restrictive than the federal framework. Procurement teams working with US-based suppliers should verify the applicable state-level position before drawing conclusions from the PCAC outcome.

The FDA's own scientists recommended against all seven peptides in their pre-meeting briefing documents, citing inadequate characterisation and insufficient evidence of effectiveness. The FDA is not bound by the panel's recommendations, and any change would require a formal rulemaking process. Whether the agency accepts, modifies or declines to act on the committee's six positive recommendations will be the next significant milestone to track.